Global Retirement Partners LLC Acquires Shares of 444 IDEXX Laboratories, Inc. $IDXX

Global Retirement Partners LLC bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 444 shares of the company’s stock, valued at approximately $238,000.

A number of other large investors have also recently made changes to their positions in the stock. Mutual of America Capital Management LLC increased its holdings in IDEXX Laboratories by 79.6% during the 1st quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock worth $8,160,000 after purchasing an additional 8,609 shares during the period. Arkadios Wealth Advisors bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth $405,000. Plato Investment Management Ltd increased its stake in shares of IDEXX Laboratories by 37.1% during the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock valued at $1,310,000 after buying an additional 835 shares during the period. Genesis Wealth Advisors LLC bought a new stake in shares of IDEXX Laboratories in the second quarter valued at about $215,000. Finally, ORG Wealth Partners LLC purchased a new stake in IDEXX Laboratories in the second quarter worth about $273,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on IDXX shares. Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a report on Monday, November 3rd. JPMorgan Chase & Co. upped their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. BTIG Research lifted their price target on IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Finally, Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $730.50.

Insider Activity at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. This trade represents a 30.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $728.97 on Tuesday. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The firm has a market cap of $58.21 billion, a PE ratio of 60.70, a P/E/G ratio of 4.06 and a beta of 1.62. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The stock has a fifty day moving average price of $668.65 and a 200-day moving average price of $607.93.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.08. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.